The strong revenue growth, particularly in Decipher (27% growth) and Afirma tests, combined with margin expansion and robust cash flow, suggests improving fundamentals. The reiterated 2026 guidance provides visibility, but investors should monitor the impact of new product launches (Prosigna LDT, TrueMRD) on future growth.
Price Chart
Executive Summary
Veracyte reported strong fourth quarter and full year 2025 financial results, with Q4 total revenue up 19% year-over-year to $140.6 million and full year revenue up 16% to $517.1 million. The company delivered GAAP net income of $66.4 million and generated $136.3 million in operating cash flow. Management reiterated 2026 revenue guidance of 10-13% growth.
Key Financial Metrics
Key Facts
- Q4 2025 total revenue: $140.6 million (19% YoY growth)
- Full year 2025 total revenue: $517.1 million (16% YoY growth)
- Q4 2025 GAAP net income: $41.1 million (29.3% of revenue)
- Full year 2025 GAAP net income: $66.4 million (12.8% of revenue)
- Generated $136.3 million in cash from operations for full year 2025
- Reiterated 2026 revenue guidance of $570-$582 million (10-13% growth)
Financial Impact
Revenue growth of 16-19% and net income growth of 175% YoY with strong cash flow generation of $136.3 million
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Decipher | $310.7M | +27.0% |
| Afirma | $172.9M | +9.0% |
Risk Factors
- Biopharmaceutical and other revenue declined due to restructuring of Veracyte SAS
- Future guidance excludes contribution from new tests, creating uncertainty about full-year performance
- Adjusted EBITDA margin expected to decrease to ~25% in 2026 from 27.6% in 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001384101-26-000008 |
| Document: vcyt-20260225.htm | 0001384101-26-000008 |
| Document: 0001384101-26-000008-index-headers.html | 0001384101-26-000008 |
| Document: 0001384101-26-000008-index.html | 0001384101-26-000008 |
| Document: 0001384101-26-000008.txt | 0001384101-26-000008 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | Press Release | $40.14 $43.36 | ▲ +8.02% | ▲ +5.89% | $45.61 (+13.63%) |
Sep 4, 2026 27d ago | Insider Cluster | $42.45 $40.14 | ▼ −5.44% | ▼ −4.32% | $45.61 (+7.44%) |
Jun 18, 2026 15w ago | 144 | $53.19 $60.49 | ▲ +13.72% | ▲ +15.79% | $45.61 (−14.25%) |
Jun 11, 2026 16w ago | Institutional Cluster | $47.33 $53.63 | ▲ +13.31% | ▲ +12.64% | $45.61 (−3.63%) |
Jun 5, 2026 17w ago | Insider Cluster | $48.73 $47.33 | ▲ +2.87% | ▲ +3.44% | $45.61 (+6.40%) |
Jun 5, 2026 17w ago | Insider Cluster | $48.73 $47.33 | ▼ −2.87% | ▼ −3.44% | $45.61 (−6.40%) |
May 27, 2026 18w ago | Insider Cluster | $47.99 $49.94 | ▲ +4.06% | ▲ +3.75% | $45.61 (−4.96%) |
May 20, 2026 19w ago | 144 | $45.19 $47.99 | ▲ +6.20% | ▲ +4.60% | $45.61 (+0.93%) |
May 5, 2026 21w ago | 8-K | $41.19 $39.56 | ▼ −3.96% | ▼ −5.09% | $45.61 (+10.73%) |
Apr 22, 2026 23w ago | DEFA14A | $33.15 $31.78 | ▼ −4.13% | ▼ −5.61% | $45.61 (+37.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access